How Will The Chemotherapy-Induced Neutropenia Treatment Market Expand At A CAGR Of 5.2% Through 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The Chemotherapy-Induced Neutropenia Treatment Market?
In recent times, there has been robust growth in the market size of treatments for chemotherapy-induced neutropenia. Anticipated to rise from $0.59 billion in 2024, the market is projected to reach $0.62 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.4%. The notable growth in the past era can be ascribed to factors such as the escalating incidence of cancer, increasing acceptance of chemotherapy, rise in the elderly population, elevated rates of hospitalization due to infections, and the broadening of oncology drug pipelines.
Prospects for the market size of chemotherapy-induced neutropenia treatment are optimistic, with anticipated robust growth in the coming years. By 2029, estimates place the market at $0.76 billion, boasting a compound annual growth rate (CAGR) of 5.2%. A number of factors contribute to this expected growth in the forecast period, including a growing demand for specific neutropenia therapies, stepped-up investment in research and development in oncology, a greater emphasis on outpatient care, wider usage of biosimilars, and increased public awareness about preventing infections. Additionally, key trends predicted for the forecast period encompass the creation of longer-lasting granulocyte colony-stimulating factor therapy (G-CSF) agents, an upward trend in the use of combined therapies, a rising preference for solutions that allow home-based care, an uptick in the approval of biosimilars, and the integration of digital health tracking tools.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
What Drivers Are Accelerating Expansion Of The Chemotherapy-Induced Neutropenia Treatment Market?
Growth in the chemotherapy-induced neutropenia treatment market is anticipated to be fuelled by the rising prevalence of cancer. Cancer is a collection of diseases typified by uncontrolled growth and diffusion of abnormal cells in the body. The escalation in cancer rates is attributable to the old age population, who are at a higher risk of cancer due to amassed genetic mutations and degenerating immune function. Chemotherapy-induced neutropenia treatment plays a crucial role in cancer management by lowering infection hazards through boosting immunity, enabling fewer disruptions in chemotherapy sessions. By keeping complications at bay, it improves treatment results, thereby enhancing patient safety and quality of life. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that cancer diagnoses in Australia grew to 160,570 in 2022, up by 3,789 cases from 156,781 in 2021. Thus, the escalating prevalence of cancer is propelling the growth of the chemotherapy-induced neutropenia treatment market.
What Are The Primary Segmentation Parameters In The Chemotherapy-Induced Neutropenia Treatment Market?
The chemotherapy-induced neutropenia treatmentmarket covered in this report is segmented –
1) By Type: Antibiotic Therapy; Granulocyte Colony-Stimulating Factor Therapy (G-CSF); Granulocyte Transfusion; Other Types
2) By Route of Administration: Subcutaneous; Intravenous
3) By Indication: Solid Tumors; Hematological Malignancies; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Specialty Clinics; Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics; Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim; Pegfilgrastim; Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion; Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy; Stem Cell Therapy; Immunomodulatory Therapy
Which Emerging Trends Are Reshaping The Chemotherapy-Induced Neutropenia Treatment Market Landscape?
Leading corporations in the chemotherapy-induced neutropenia treatment market are centring their efforts on the enhancement of innovative products and securing approvals, like long-acting formulations, in order to boost treatment adherence, lessen the frequency of doses, and upgrade patient comfort levels. Long-acting formulations are essentially drug concoctions designed to slowly discharge active substances over prolonged periods, subsequently bringing down the frequency of administration. For example, Coherus BioSciences Inc., a biopharmaceutical enterprise based in the US, was granted approval by the U.S. Food and Drug Administration (FDA) for its novel, ready-to-use on-body injector, Udenyca Onbody, in December 2023. This device, embedded with a long-acting preparation, intuitively administers pegfilgrastim around 27 hours post-chemotherapy, thereby removing the requirement for a subsequent day’s injection. Udenyca Onbody augments the patient experience by guaranteeing timely preventive treatment for chemotherapy-induced neutropenia while also lessening clinic visitations and boosting adherence.
Which Players Are Shaping The Competitive Landscape Of The Chemotherapy-Induced Neutropenia Treatment Market?
Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Chemotherapy-Induced Neutropenia Treatment Market?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp
Browse Through More Reports Similar to the Global Chemotherapy-Induced Neutropenia Treatment Market 2025, By The Business Research Company
Ambulatory Iv Infusion Pumps Global Market 2025
https://www.thebusinessresearchcompany.com/report/ambulatory-iv-infusion-pumps-global-market
Chemotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
